Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edgar Dippel

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 28, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 2, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers of Medicine|July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trialElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 28, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 2, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers of Medicine|July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trialElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Pageof 10